82 results about "Transcriptional repression" patented technology

The invention discloses application of a TaLBD30 protein and a coding gene thereof in regulating and controlling a wheat plant type. The invention belongs to the technical field of biology, and particularly relates to application of TaLBD30 protein and a coding gene thereof to regulation and control of wheat plant types. The protein is any one of the following proteins: A1) a protein with an amino acid sequence as shown in SEQ ID No: 1; a2) a protein which is obtained by substitution and / or deletion and / or addition of amino acid residues on the protein of A1), has 80% or more of identity with the protein of A1) and has the same function as the protein of A1); a3) a fusion protein obtained by connecting a protein tag to the N terminal or / and the C terminal of A1) or A2). TaLBD30 is a transcription factor with transcription inhibition activity, and compared with a wild type, the TaLBD30 gene overexpression shows that after TaLBD30 overexpression, the wheat plant height and ear length are remarkably reduced.

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and / or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.

Provided in some aspects are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA systems, that bind to or target a target site in a gene or regulatory element thereof in a T cell. In some aspects, the provided epigenetic modifying DNA-targeting systems provided herein modulate a T cell phenotype or activity. In particular, the provided embodiments relate to the transcriptional repression of genes to promote a stem cell-like memory T (TSCM) cell phenotype. In some aspects, also provided are compositions, polynucleotides, vectors, cells, and pluralities and combinations thereof, and methods and uses related to the provided epigenetic-modifying DNA-targeting systems, for example in modulating the phenotype in T cells including in connection with adoptive T cell therapy.

The invention relates to application of a UHRF1 inhibitor in preparation of a medicine for treating tissue fibrosis after spinal cord injury, and belongs to the technical field of biological medicine. The invention proves that the expression of UHRF1 can be increased due to spinal cord injury; compared with mice of a false operation group, the mice of which the UHRF1 is specifically knocked down in the fibroblasts have the advantages that fibrosis caused by spinal cord injury is obviously reduced, nerve regeneration is promoted, and the motor function is obviously improved. In the aspect of mechanism, the knock-down of UHRF1 leads to the reduction of the number of proteins combined on a PPM1A gene promoter, the weakening of the transcription inhibition effect and the promotion of the expression of the PPM1A gene, while the PPM1A can inhibit the phosphorylation of Smad2 / 3 and inhibit the conduction of a TGF-beta1 / Smads pathway, thereby inhibiting tissue fibrosis.

The invention relates to an application of an IGF-1R (Insulin-like Growth Factor-1 Receptor) gene expression inhibitor in preparation of a medicine for delaying senescence and improving senile diseases, siRNA (Small Interference Ribonucleic Acid) aiming at an IGF-1R gene is designed by using a gene interference technology and is chemically modified, and expression of the gene and a downstream signal channel of the gene are inhibited by inhibiting transcription of the IGF-1R gene. Compared with a middle-aged control mouse, under the condition of inhibiting the IGF-1R, the hair condition, the athletic ability and the learning and memory functions of the middle-aged mouse are obviously improved, and the middle-aged mouse is even similar to an adult mouse, so that the IGF-1R gene is an important factor for delaying senescence, and therefore, the IGF-1R gene can be used as an anti-aging mouse. A medicine for inhibiting the expression of the IGF-1R gene is designed by taking the IGF-1R gene as a target, a new direction can be provided for research and development of anti-aging and senile disease prevention medicines, and the IGF-1R gene has a very good anti-aging target application prospect.

The present invention relates generally to compositions, systems and methods for modulating hepatitis B virus (HBV) by targeting gene repression. In particular, the present invention provides an epigenetically modified DNA targeting system, such as a CRISPR-Cas / guide RNA (gRNA) system, for transcriptional repression of hepatitis B virus genes to promote cell phenotypes that lead to reduced HBV infection. In some embodiments, the epigenetically modified DNA targeting systems of the present invention bind to or target a target site of at least one gene in the hepatitis B virus DNA sequence or a regulatory element thereof in a cell. In some aspects, the systems provided herein relate to transcriptional repression of one or more hepatitis B virus genes and / or regulatory elements thereof. In some aspects, the invention also provides methods and uses associated with the provided compositions, such as in repression of hepatitis B virus replication and expression associated with hepatitis B infection.

Compositions comprising biologically active synthetic nanoparticle constructs and methods of use thereof to modify mitochondrial gene expression including transcriptional repression and transcriptional activation.

To provide, generally, methods and compositions for transferring a genetic circuit from one prokaryotic cell ("donor cell") to another prokaryotic cell ("recipient cell" or "target cell" used interchangeably herein).SOLUTION: The present disclosure relates to: prokaryotic donor cells comprising (i) a genetic circuit of interest and (ii) one or more expressed transcriptional repressor proteins; and the use of the donor cells in efficient transfer of the genetic circuit into a prokaryotic recipient cell. The genetic circuit includes nucleic acid sequences encoding an RNA molecule or protein of interest.SELECTED DRAWING: None

The present invention discloses a genetically engineered bacterium producing L-threonine and a construction method and application thereof. The present invention strengthens the biotin synthesis of the L-threonine producing strain by strengthening the bioABFCD gene (including promoter strengthening, RBS sequence strengthening, and multiple copies), relieving the transcriptional repression of the birA gene, and relieving the transcriptional repression of birA while strengthening bioABFCD. The constructed genetically engineered bacterium producing L-threonine can produce up to 20.2 g / L of L-threonine and a sugar-acid conversion rate of 23.8% after fermentation culture.

The invention discloses an application of an activator combined by one or more genes / proteins in preparation of drugs for treating hypertrophic scars, and belongs to the technical field of biological medicines. In order to solve the problem that when retinoic acid cream is used for preparing hypertrophic scars, a specific mode and an action target of a retinoic acid signal channel for regulating and controlling fibroblasts are not disclosed yet, the action target and a regulation and control mechanism of ATRA for regulating and controlling fibroblast activation and glucose metabolism remodeling are explored through in-vivo and in-vitro experiments; and on the basis of a Cre-loxP system, the function of the target gene is verified. Researches in the invention show that ATRA promotes transcription of HIC1 and inhibits transcription and expression of TGF-beta1 by activating RAR alpha on one hand, and ATRA promotes transcription of HIC1 and inhibits transcription and expression of TGF-beta1 on the other hand; on the other hand, the transcription of PCK1 and PCK2 is promoted, so that the proliferation and abnormal activation of HSFs are reduced, and the occurrence and development processes of hypertrophic scars are finally inhibited. The conclusion provides a sufficient theoretical basis for inhibiting hypertrophic scar formation by ATRA.

A complex comprising a first fusion and a second fusion, wherein one of the first fusion and the second fusion comprises a DNA methylation domain and at least one recruitment domain A, and the other fusion comprises a transcriptional repressor domain and at least one recruitment domain A', wherein the recruitment domain A and the recruitment domain A' are capable of interacting with each other such that one of the first fusion and the second fusion, or a portion thereof, can be recruited to the vicinity of the other fusion. Further provided is the use of the complex in the manufacture of a product for silencing expression of a target gene and in the manufacture of a medicament.

A clustered regularly interspaced short palindromic repeat (CRISPR)-associated complex for adaptive antiviral defence (Cascade); the Cascade protein complex comprising at least CRISPR-associated protein subunits Cas7, Cas5 and Cas6 which includes at least one subunit with an additional amino acid sequence possessing nucleic acid or chromatin modifying, visualising, transcription activating or transcription repressing activity. The Cascade complex with additional activity is combined with an RNA molecule to produce a ribonucleoprotein complex. The RNA molecule is selected to have substantial complementarity to a target sequence. Targeted ribonucleoproteins can be used as genetic engineering tools for precise cutting of nucleic acids in homologous recombination, non-homologous end joining, gene modification, gene integration, mutation repair or for their visualisation, transcriptional activation or repression. A pair of ribonucleotides fused to FokI dimers may be used to generate double-strand breakages in the DNA to facilitate these applications in a sequence-specific manner.

The application discloses high-temperature-resistant engineered methanotrophs with high glutamic acid yield, a construction method and application thereof, and belongs to the field of industrial biotechnology. Methylotuvimicrobium buryatense 5GB1 as the host strain, transcriptional inhibition of the SOS response system by LexA protein is removed by knocking out a lexA gene in the genome of the host strain, expression of DNA damage repair related genes in the cell is activated, and high-temperature-resistant engineered methanotrophs MBΔ lexA that can stably grow in a high-temperature environment of 40-45 DEG C are obtained. The strain can still maintain normal growth and metabolism with methane as the sole carbon source under the condition of 40-45 DEG C, and the glutamic acid synthesis capacity of the strain is significantly better than that of the original strain at normal temperature. The high-temperature-resistant engineered methanotrophs MBΔ lexA provide important strain resources for the production of amino acid products by methanotroph cell factories in a high-temperature industrial scene, and are expected to improve the economy and sustainability of methanotrophic bioconversion.

This invention belongs to the field of plant molecular biology and genetic breeding technology, specifically relating to a molecular marker related to the malic acid content of apple fruit and its application. The molecular marker is... MdNAC029 The single nucleotide polymorphism site in the gene promoter region, this site is located MdNAC029 The nucleotide sequence of the gene promoter region, starting from the 2693rd base at the 5' end, corresponds to... MdNAC029 At a position 442 bp upstream of the transcription start codon, the polymorphism is either T or C, with the C / C genotype indicating high malic acid content and the T / T genotype indicating low malic acid content. This invention, through molecular biology experiments, confirms that the T allele is the binding site for the transcriptional repressor MdMYC2, and the C allele eliminates the binding of MdMYC2, thereby relieving transcriptional repression and promoting malic acid accumulation. This provides a new molecular marker for the genetic improvement of apple fruit acidity traits, accelerating the breeding process of superior varieties.

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and / or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.

Provided in some aspects are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems for the transcriptional repression of genes to promote a cellular phenotype that leads to reduction of low-density lipoprotein (LDL). In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof that regulate LDL. In some embodiments, the systems are multiplexed systems that bind to or target a target site in at least two genes or regulatory elements thereof. Also provided herein are methods and uses related to the provided epigenetic-modifying DNA targeting systems in connection with treatments for cardiovascular disease and familial hypercholesterolemia.

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and / or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and / or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.

The present invention discloses a Pennisetum gracilis light-responsive transcription factor gene PgGRAS54 and application thereof for improving the cold resistance of plants, and belongs to the field of genetic engineering technology. The CDS sequence of the Pennisetum gracilis light-responsive transcription factor gene PgGRAS54 is shown in SEQ ID NO.9. The gene is located in the cell membrane and the nucleus, and exhibits obvious transcription inhibition activity in yeast and tobacco systems, indicating that PgGRAS54 is a transcription inhibitor that responds to light and cold. Further studies have found that overexpression of PgGRAS54 enhances the cold resistance of Arabidopsis thaliana by increasing the expression level of the COR gene. The PgGRAS54 gene provided by the present invention is of great significance for improving the cold resistance of Pennisetum gracilis and expanding its distribution in high-latitude areas, and at the same time provides a theoretical basis for breeding highly cold-resistant plants.

The invention discloses a preeclampsia (PE) diagnosis and treatment biological marker and an application of the preeclampsia PE diagnosis and treatment biological marker. The mechanism that overexpressed FBP2 causes PE generation by inhibiting trophoblast invasiveness is deeply demonstrated from clinical samples, cells and in-vivo levels, it is verified that NOTCH3 downstream classical gene HEY1 can be combined with an FBP2 promoter region and transcriptionally inhibits expression of the FBP2, the FBP2 is combined with c-MYC protein and inhibits c-MYC transcriptional activity, TFAM transcriptional expression is down-regulated, and the expression of the FBP2 is inhibited. The mechanism which causes mitochondrial dysfunction, weakens the migration and invasion ability of trophoblasts and participates in PE generation is a new mechanism clue obtained according to a pre-experiment result and informatics analysis and is a new target for deeply exploring PE clinical diagnosis and treatment, and research results can provide a theoretical basis for guiding PE early prediction and intervention in the future.

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and / or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.

A method for increasing protein content in a eukaryotic cell comprising a NF‑YC4 gene, the method comprising modifying a transcriptional repressor binding site; a method for producing a plant with increased protein content, the method comprising crossing and selecting for increased protein content; a method for increasing resistance to pathogens or pests in a plant cell or plant comprising a NF‑YC4 gene, the method comprising modifying a transcriptional repressor binding site, alone or in combination with expressing QQS in the plant cell or plant; a method for producing a plant with increased resistance to pathogens or pests, the method comprising crossing and selecting for increased resistance to pathogens or pests; a cell, a collection of cells, a tissue, an organ or an organism such as a plant, wherein the NF‑YC4 gene comprises a promoter, the promoter comprising a modified transcriptional repressor binding site such that the transcriptional repressor cannot hinder NF‑YC4 transcription; a hybrid plant; and seeds.

The application discloses a kind of preeclampsia (Preeclampsia, PE) diagnosis and treatment biology marker and its application;The application is from clinical sample, cell and in-depth demonstration of overexpressed FBP2 at the level of body, which causes the mechanism of PE occurrence by inhibiting the invasion of trophoblasts, and the application verifies that the classic gene HEY1 downstream of NOTCH3 can be combined with the promoter region of FBP2 and transcribe to inhibit the expression of FBP2, FBP2 is combined with c-MYC protein and inhibits the transcriptional activity of c-MYC, down-regulates the transcriptional expression of TFAM, causes mitochondrial dysfunction, weakens the migration and invasion ability of trophoblasts, participates in the mechanism of PE occurrence, is a new mechanism clue obtained according to the results of pre-experiment and information analysis, is a new target for in-depth exploration of PE clinical diagnosis and treatment, and the research results can provide theoretical basis for guiding early prediction and intervention of PE in the future.

Disclosed herein are Type I Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) / CRISPR-associated (Cas) programmable systems and methods of using said Type I CRISPR / Cas programmable systems for activating gene expression, repressing gene expression, and gene editing. The disclosure relates to compositions that include Type I CRISPR-Cas fusion proteins designed for transcriptional activation, transcriptional repression, and / or gene editing of target genes in eukaryotic cells. The disclosure relates to Type I Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) / CRISPR-associated (Cas) transcriptional activation system related compositions and methods of using said Type I CRISPR / Cas transcriptional activation system related compositions for activating gene expression. The disclosure relates to compositions that include a Type I CRISPR-Cas fusion protein designed for transcriptional activation of target genes in eukaryotic cells.

According to the application of the rosiglitazone in preparation of the medicine for treating the glioma and the composition of the rosiglitazone, a brand-new Rb-E2F1-mediated MND1 transcription inhibition mechanism of the rosiglitazone in the glioma is clarified for the first time; and a new strategy with a great transformation prospect is provided for treatment of glioma, namely, a clinical drug rosiglitazone which has been subjected to security certification is utilized to interfere DNA repair steady state of glioma cells through targeted inhibition of MND1, so that tumor growth is inhibited.

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and / or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.

The present invention relates to the use of an inhibitor of UHRF1 in the preparation of a medicament for treating tissue fibrosis after spinal cord injury, belonging to the technical field of biomedicine. The present invention has confirmed that spinal cord injury can lead to an increase in the expression of UHRF1; compared with the mice in the sham operation group, the mice with specific knockdown of UHRF1 in fibroblasts significantly reduced the fibrosis caused by spinal cord injury and promoted nerve regeneration, and the motor function was significantly improved. In terms of mechanism, the knockdown of UHRF1 led to a decrease in the number of its proteins bound to the promoter of the PPM1A gene, resulting in a weakened transcriptional inhibitory effect, promoting the expression of the PPM1A gene, and PPM1A can inhibit the phosphorylation of Smad2 / 3 and inhibit the conduction of the TGF-β1 / Smads pathway, thereby inhibiting tissue fibrosis.

The present application relates to an engineered gene transcriptional repression tool and a use thereof, in particular to an epigenetic editor, comprising a transcription activator-like effector (TALE) domain, at least one epigenetic modification domain, and at least one transcriptional regulatory domain, wherein the domains can be directly or indirectly linked; or the domains form various fusions and interact by means of recruitment.

Provided is an epigenetic editor comprising a transcriptional activator-like effector (TALE) domain, at least one epigenetic modification domain, and at least one transcriptional regulatory domain; wherein the TALE domain can be specifically combined with a target nucleotide sequence on an HBV (Hepatitis B Virus) gene and / or a regulatory element of the HBV gene.

The application discloses TaLBD30 protein and an application of a coding gene thereof in regulating a wheat plant type, and belongs to the technical field of biotechnology, and particularly relates to the application of the TaLBD30 protein and the coding gene thereof in regulating the wheat plant type. The protein is any one of the following: A1) a protein with an amino acid sequence as shown in SEQ ID No:1; A2) a protein obtained by substitution, deletion and / or addition of amino acid residues on the protein of A1), the protein being identical to the protein shown in A1) by more than 80% and having the same function; and A3) a fusion protein obtained by connecting a protein tag to the N terminal or / and C terminal of A1) or A2). The TaLBD30 is a transcription factor with transcription inhibition activity, and when overexpressed TaLBD30 , the wheat plant height and ear length are significantly reduced compared with a wild type. TaLBD30 ​